Statistics from Altmetric.com
Our study did not include specific dietary counselling of patients, and there was no concerted effort to have patients adhere to a specific hypocaloric regimen. During follow-up visits, patients underwent per protocol (PP) dietary counselling based on standard clinical practice guidelines. These guidelines emphasise the relation of carbohydrate intake, glycaemic index and blood glucose control. Taking into account that patients willing to participate in a study are generally more motivated to make behavioural changes, it is possible that the subjects in this study reduced their total carbohydrate intake during this study. However, since we did not record specific data on dietary intake, we cannot address this issue.
Regarding the food preference after bariatric procedures: indeed there is some evidence of food preference changes in patients who have undergone gastric bypass surgery. However, this evidence is large based on indirect measurements, mostly patients’ self-reporting.3 More recent studies, in which changes in food preferences were directly assessed, contradict previous findings and/or warn for over interpreting self-reported changes in food preference.4
The weight loss observed in this study might also be a confounding factor. However, the total weight loss of ~2.3 kg observed occurred in the first 4 weeks of the study when patients were on a liquid diet transitioning into solid foods over 2 weeks postprocedure, after which weight stabilised. In our opinion, the limited weight loss and its course over time do not suggest that this is a major confounding factor in our study.
Johnston and colleagues inquire if the baseline characteristics of the PP population are comparable to those of the intention-to-treat (ITT) population. The online supplementary table indicates that the baseline characteristics were comparable.
In our opinion, it is not accurate to use the nine excluded patients as control group to compare efficacy to the ITT population: all nine excluded patients underwent at least a partial duodenal ablation (two patients underwent two ablations; one patient had three ablations; and six patients had four ablations) and therefore will have had some therapeutic effect. Fortunately, data of a sham-controlled randomised study will come available shortly.
Our team is eager to elucidate the underlying mechanism how duodenal ablation improves glycaemic and metabolic health in patients with type 2 diabetes. The considerations raised by Johnston and colleagues will be taken into account when designing new studies of duodenal ablation in patients with type 2 diabetes.
Contributors Suzanne Meiring (SM), Kelly White (KW) and Jacques Bergman JJGHMB contributed equally in writing this letter.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests This study was funded by Fracyl Laboratories.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.